Researchers evaluated pirtobrutinib in a small group of 36 patients with relapsed or refractory marginal zone lymphoma. The group included patients with extranodal, nodal, and splenic forms of the disease. The study aimed to see how many patients achieved an objective response and to check safety over a follow-up period of about 32 months.
The results showed that 55.6% of patients had an objective response, meaning their tumors shrank significantly. Among those who responded, three patients achieved a complete response, while 17 had a partial response. The average time a response lasted was 17.8 months, and progression-free survival averaged 16.6 months. Overall survival could not be estimated due to the small number of patients.
Safety was generally good, with the drug being well tolerated. However, four patients needed dose reductions and four others stopped treatment due to side effects. Because this is an early-phase trial with a small sample size, these findings should be viewed as preliminary. More research is needed to confirm these benefits and to determine if this treatment should be used widely.